Curia's Biologics Discovery and Development Capabilities
Learn More
Discovery
Platforms
Single B cell with the Berkeley Lights Beacon® Optofluidic System
Platform
TunaCHO™, a proprietary technology platform for CHO transient production, delivering the highest production yield compared to other commercial cell lines
Development
Validate and accelerate your compound
Process development
Commercial mindset from the start to accelerate timelines to clinic.
- Optimize cell productivity in single-use bioreactors (SUB)
- Performed for all protein-based technologies
- Demonstrated success with purification schemes for hundreds of unique proteins for pre-clinical toxicology material
CHO-GSNSM platform stable cell line development service
Our platform uses its proprietary cell line, custom stable expression vectors, and glutamine synthetase (GS) selection technology, maximizing purity and yield while minimizing the time between development and toxicology studies.
Analytical method development and services to optimize assay design, capacity and execution
Wide range of molecular, biochemical and cell-based bioassays
Comprehensive method development meeting USP, Ph. Eur., and FDA guidelines
Expertise from discovery to cGxP therapeutic testing for all service types
Formulation development services
Fully integrated formulation development programs that emphasize critical quality attributes with ICH stability guidelines and manufacturability in mind
mRNA development services
End-to-end solutions covering mRNA synthesis, formulation and lipid nanoparticle fill-finish
Manufacturing
Rely on our expertise
Our complete suite of services and solutions for mRNA, monoclonal antibodies and recombinant proteins.
Drug substance
Our Hopkinton, MA facility is ISO 13485:2016 certified and provides biomanufacturing services for GMP and BPG production of mRNA, protein therapeutics and vaccines, and therapeutic antibodies.
- Established quality system supports production of early-phase bulk drug and diagnostic products
- End-to-end solutions cover mRNA, protein and antibody large scale production, in-process testing and batch release, lipid nanoparticle (LNP) fill-finish — all manufactured in ISO 7 suites with GMP-compliant single-use equipment
Drug product
Our Glasgow, UK and Camarillo, CA sites offer expertise and capabilities for sterile drug product manufacturing from early clinical through large-scale supply.
- Providing a complete suite of services for all sterile dosage forms — liquid, suspension or lyophilized
- Covering a broad range of therapeutics in mRNA, proteins, mAbs, peptides, oligonucleotides to deliver large-scale fill-finish needs
Biologics Formulation and Fill-Finish Capabilities at Curia
With over 30 years of experience formulating both large and small molecules for injection, we can identify the quality attributes that impact the clinical performance and safety of formulations, analyze the manufacturability of dosage forms, and assess stability in primary packaging. Watch video
